Research Policies & Forms
From writing your initial proposal to statistical requests and patient & public involvement, here you will find all the documents, forms and standard operating procedures you will need to develop and set up your research idea at North Bristol NHS Trust.
Our Standard Operating Procedures (SOPs) should be used by Chief and Principal Investigators, Research Nurses and all other research personnel. They provide detailed guidance on all aspects of research study management from design through to completion.
If you are an NBT staff member, the current research SOPs should first be accessed via our Managed Learning Environment (MLE) in accordance with the Research Staff Training SOP. This will provide you with an electronic training record to evidence that you have read each SOP.
It is the responsibility of all staff who carry out research to ensure you are using the latest SOP.
Some of the documents are available online below. If you would like a document that is not available online, please contact: research@nbt.nhs.uk.
Policies & Guidance
R&D - (PO1) Commercial Research Policy
R&D - (PO2) Sponsorship & Central Trial Management Fees Policy
R&D – (P03) Excess Treatment Costs In Research at NBT has been suspended. All new research projects with excess treatment costs require approval from the General Manager/Clinical Director.
R&D - (PO4) NIHR Research Funding Recovery Policy
R&D - (PO5) - PPI in Research Payment Policy
R&D - (P06) Research Misconduct Policy
R&D P07 Safeguarding in Research Policy
R&D (GD 012b) Identifying & preventing noncompliance with Good Clinical Practice or the protocol
NBT (CG-134) Adult Safeguarding Policy
NBT (CG-197) Safeguarding Children Policy
NBT (PEO-33) Fairness at Work Policy
Standard Operating Procedures
BFT SOPs
BRD/QMS/SOP/001 Interim SOP for Research Compliance
NBT SOPs
RD/QMS/SOP/001 : Preparation of Research Standard Operation Procedures
RD/QMS/SOP/002 : Obtaining R&D Confirmation for Research to Start
RD/QMS/SOP/003 : Research Study Modifications
RD/QMS/SOP/004 : Maintenance of Research Equipment SOP
RD/QMS/SOP/005 : Research Staff Training
RD/QMS/SOP/006 : Honorary Research Contract Letters of Access
RD/QMS/SOP/006a External Researcher Information Form
RD/QMS/SOP/007 : Applying for NBT Sponsorship
RD/QMS/SOP/007b NBT Terms & Conditions of Sponsorship
RD/QMS/SOP/007c Delegation of Responsibilities
RD/QMS/SOP/008 : Writing a Protocol for CTIMPS
RD/QMS/SOP/009 Periodic Reporting to Regulatory Authorities
RD/QMS/SOP/010 : Archiving
RD/QMS/SOP/011: R&D Closing Suspending and Terminating Research
RD/QMS/SOP/012 : R&D Managing Breaches of GCP or the Protocol
RD/QMS/SOP/012a : ICH GCP NonCompliance Report Form
RD/QMS/SOP/012c : Protocol Deviation Review & Analysis Form
RD/QMS/SOP/013 : R&D Safety Reporting CTIMPS
RD/QMS/SOP/014 : R&D Monitoring
RD/QMS/SOP/015 : R&D Computer System Validation & Backup
RD/QMS/SOP/016 : R&D Vendor Selection and Management
RD/QMS/SOP/017 : R&D Data Management
RD/QMS/SOP/018: R&D Management of Fridges & Freezers
RD/QMS/SOP/020 : Management of healthy volunteers in research
RD/QMS/SOP/021 : R&D Informed Consent in Adult Research Setting
Templates
QMS/TMPL/001/File Note
RD/QMS/TMPL/SOP 007a Sponsorship Request Form
RD/QMS/TMPL/SOP 007d Delegation of Responsibilities Log
RD/QMS/TMPL/SOP 007e CI Declaration Form
RD/QMS/TMPL/009 DSUR Template
RD/QMS/TMPL/012a ICH GCP + Protocol Non-compliance Report Form
RD/QMS/TMPL/012c Protocol Deviation Review + Analysis Form
RD/QMS/TMPL/013a Initial Safety Report Form- CTIMP
RD/QMS/TMPL/013b Follow Up Report Form - CTIMP
Research Ethics
At North Bristol NHS Trust, we are committed to ensuring that all research conducted within our organisation upholds the highest standards of ethical integrity, safeguarding the rights, dignity, safety and wellbeing of everyone involved.
We support high-quality, ethical research that contributes to improving patient care, public health, and service delivery.
Ethical Review Process
All research involving our patients, staff, data or facilities must receive appropriate ethical review and approval before it begins. This may include:
- Review by a Health Research Authority (HRA) Research Ethics Committee (REC) – required for most research involving patients or identifiable NHS data.
- Local review through the Trust’s Research & Development (R&D) Department, which ensures projects meet NHS and Trust-specific governance requirements.
We work closely with the HRA to ensure compliance with the UK Policy Framework for Health and Social Care Research and all relevant legal and ethical standards, including GDPR and the Declaration of Helsinki.
The HRA provides comprehensive guidance on the ethical review process, including the roles and responsibilities of RECs to ensure that we protect the rights, safety, dignity and wellbeing of participants.
This centralised approach ensures consistency and rigour in the ethical review of health and social care across the UK.
You can find out more information here:
Supporting Researchers
Our R&D team offers support and guidance throughout the ethical approval process. We help researchers:
- Identify the appropriate level of ethical review
- Prepare and submit applications via the Integrated Research Application System (IRAS), including development of the required submission documents such as research protocol, participant information sheets and consent forms.
- Understand key ethical considerations such as consent, confidentiality, risk, and public involvement.
If you are planning a research project, please contact our R&D team early in your planning process to ensure ethical requirements are met, as part of our sponsorship review process.
Contact Us
For further information or support with research ethics, please contact:
Research and Development
Research Sponsor
North Bristol NHS Trust
Email: researchsponsor@nbt.nhs.uk
Phone: 0117 414 9330
View Our Research
Explore the ground-breaking research currently taking place at North Bristol NHS Trust.
About Research & Development
Find out more about our research and how we're working to improve patient care.
Contact Research
Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB
Telephone: 0117 4149330
Email: research@nbt.nhs.uk
Waiting for a second ultrasound scan
Why do I need another scan?
An ultrasound scan is the best way of finding out whether your pregnancy is developing normally, or whether there is a problem. Sometimes we are not able to get all the information that we need from one scan, so you may need to have another scan a week or two later.
What will the second scan show?
For some, the pregnancy will be developing normally. You will be asked to contact your midwife for ongoing care.
For others, the second scan will diagnose a miscarriage.
We understand that waiting for the second scan can be distressing. National guidance recommends two scans, sometimes one week apart. This is to confirm that there is no development of the pregnancy.
What happens whilst I am waiting?
If you feel well, you can continue your normal day to day activities.
If you develop vaginal bleeding or period type cramping, then we recommend that you seek advice with the Early Pregnancy Clinic. Outside working hours, please contact the Cotswold ward. This ward has nurses with experience giving advice about early pregnancy. Please contact us if you have any concerns.
If you have period type cramping you can take paracetamol if needed. You should avoid ibuprofen as this is not recommended in pregnancy.
Are there any symptoms I should report straight away?
If you have any of the following contact the Early Pregnancy Clinic or Gynaecology (Ward 78) at St Michael’s Hospital.
- vaginal bleeding soaking a pad every hour for more than four hours
- passing large blood clots (bigger than a golf ball)
- feeling unwell, dizzy, or faint
- a high temperature
- smelly vaginal discharge
You can find further information on miscarriage and sources of support available in our leaflet on miscarriage. Please request a copy of this from the nurse or doctor in clinic or on the ward. You could also visit Miscarriage UK - Because every loss matters
Early Pregnancy Clinic - 8:30am to 3:30pm
0117 414 6778
This is an answerphone and we aim to return calls within 24 hours. We are a Monday to Friday service and are not open on bank holidays.
Cotswold Ward - 24 hour number
0117 414 6785/6/8
If you are unable to contact anyone and feel unwell, call 111
Date published: 16 June 2026 Review due: 30 June 2029 PI number: BFT003853
Understanding Vestibular Schwannomas (VS)
This page explains what a vestibular schwannoma (VS) is and what it might mean for you. Your doctors and nurses can tell you more and answer your questions. At the end, there is information about groups that can help.
What is a VS?
A vestibular schwannoma, also called an acoustic neuroma, is a non-cancerous tumour. It grows on the balance nerve that
connects the inner ear to the brain. This nerve sits very close to the hearing nerve and to the facial nerve, which helps you move your face.
Because the tumour is benign, it does not spread to other parts of your brain or body.
What causes a VS?
The tumour starts in Schwann cells, which are cells that cover nerves and help them send messages. Most of the time, doctors do not know why the tumour appears. A very small number of people with a rare condition called NF2 can get tumours on both sides of the head.
Symptoms
A VS usually grows very slowly, so symptoms may take months or years to appear. Some people do not notice any symptoms at first.
As the tumour grows, it may press on nerves nearby. This can cause hearing loss, ringing in the ear, dizziness, or balance problems. If it grows more, it may cause numbness in the face, weakness in the face, pain around the ear, or trouble walking steadily.
Very large tumours can block the normal flow of fluid around the brain and cause something called hydrocephalus. This can lead to strong headaches, sickness, vision problems, nausea, memory troubles, wobbliness, or feeling extremely sleepy.
If you suddenly lose hearing in one ear or suddenly notice weakness on one side of your face, you should get urgent medical help from your doctor or go to an Emergency Department. Steroid medicine may help if it is given quickly.
Diagnosis and tests
A VS is sometimes first noticed after an unusual hearing test result. You may have more hearing tests to check how well you hear sounds and speech. Sometimes, a VS is found on a scan performed for a different reason altogether.
Most VS tumours are found using an MRI scan. This scan is safe and does not hurt. If someone finds small spaces uncomfortable, they may have be offered a mild sedative.
Some people cannot have an MRI because of metal in their body, such as a pacemaker. In that case, a CT scan can be used to make the diagnosis.
The care team (MDT)
Your care is planned by a group of specialists called the MDT (Multi-Disciplinary Team). This team includes many experts, such as brain surgeons, ENT surgeons, radiotherapy doctors, scan specialists, specialist nurses, and a coordinator. They look at your symptoms, age, your general health, the size of the tumour, and how fast it is growing. Your consultant will talk to you about what the team suggests.
Treatment options
Watch and wait
If the tumour is small/medium and not causing problems, you may not need treatment straight away. Instead, you may have regular MRI scans to check whether it is growing.
Radiotherapy
If the VS is growing, or a reasonable size when it is discovered, the MDT may suggest radiotherapy. Radiotherapy uses powerful energy beams to damage the tumour cells, so they stop growing. A common method is called Gamma Knife, which many people have in one day, although sometimes treatment takes place over several days or weeks.
Radiotherapy for VS is done at the Bristol Oncology Centre. If the MDT suggests radiotherapy, you will be seen by the Oncology team at the Bristol Haematology and Oncology Centre. The Oncology team will discuss the pros and cons of radiotherapy in more detail.
Surgery
Surgery may be needed depending on the size and position of the tumour, and the symptoms you have. This is a significant operation and needs to be planned carefully.
The tumour can be removed through the bone or skull behind the ear. Before surgery, you will meet the surgeon to talk about your symptoms, why surgery is recommended, what will happen during the operation, how long recovery might take, and any risks.
Surgery for VS is mostly non-urgent, however large tumours causing hydrocephalus require more urgent surgery. You will have time to think about your decision. The aim of the surgery is to remove as much of the tumour as possible while protecting the nerves nearby, especially the facial nerve. Sometimes a thin layer of the tumour is left behind to protect the nerve, and this area is checked later with MRI scans.
Before your surgery, you will go to a clinic where you will have an examination, blood tests, an ECG, and possibly other tests. You can ask more questions there. On the day of the surgery, you will see your surgeon and the anaesthetist again.
The operation usually takes between 8 and 12 hours. After surgery, you will spend a few days in a high-dependency unit before moving to a normal ward. Most people stay in hospital for about a week to 10 days. Feeling dizzy, sick, or unsteady is common for a while. A physiotherapist can help you learn exercises to improve your balance.
Most people lose hearing in the operated ear, and this usually cannot be fixed. A hearing therapist or audiologist can help with advice and equipment if needed. Weakness in the facial muscles may occur after large tumours are removed. This can make it hard to blink or close one eye, which may become dry. You might need eye drops, gels, or eye protection at night. Physiotherapists can show exercises to help the facial muscles and may arrange more therapy if needed.
In some rare cases, facial weakness can be more severe or last longer. Speech or swallowing can also be affected, and a speech and language therapist can help. Sometimes a feeding tube is needed for a short time.
Serious problems such as infection, meningitis, leaking brain fluid, brain damage, or hydrocephalus are rare. The risk of serious neurological or life-threatening complications are very rare. You should get urgent medical help if you notice clear fluid coming from your nose or ear, a fever, a stiff neck, headaches that get worse, vision problems, new facial weakness, or a wound that looks red or swollen.
Hearing loss
Hearing loss in one ear is the most common symptom of VS.
The other ear is not affected. This can make it harder to know where sound is coming from or to hear when there is background noise. Hearing loss caused by VS is usually permanent. It may continue to worsen in the future, even if the VS is not growing. An audiologist may suggest a hearing aid, a CROS device, or a bone-anchored hearing aid.
Tinnitus
Tinnitus means hearing a sound, such as ringing or buzzing, when nothing outside your body is making the noise. It is very common and can be worse in the ear affected by the VS. Tinnitus UK is a national charity that offers support and advice. They have an excellent website with lots of information (tinnitus.org.uk). Many audiology teams can also help with tinnitus.
Dizziness
A VS can affect the balance system in the ear, which may make you feel unsteady, especially when turning quickly or doing complicated movements. Some people have short spinning feelings called vertigo. Staying active is usually the best way to get better because it helps your body learn to balance again. Physiotherapists can teach exercises that help your balance recover. These can feel difficult at first, but most people improve over time. If dizziness suddenly becomes very bad, you should see a doctor.
Sudden changes
Sometimes symptoms can suddenly get worse. If you suddenly lose hearing in one ear within three days or notice new facial weakness, you should see your GP or go to the Emergency Department on the same day. Steroid medicine may help if it is given early. Very large tumours can cause hydrocephalus, which is serious. Strong headaches, sickness, vision problems, memory trouble, or feeling very sleepy should be checked urgently.
Driving
You can drive again once you have fully recovered from surgery. You do not need to tell the DVLA, but you should tell your insurance company. You can ask your GP to help check that you are ready to drive. You may need to inform the DVLA if you have sudden, disabling, or recurrent dizziness.
Follow-up and recovery
Follow-up
Two to three months after surgery, you will return to the Skull Base Clinic for a check-up. You will also have a phone call with a Brain Tumour Support Worker about four weeks after going home. Many people have an MRI scan around three months after surgery, and you may need more scans if a small piece of the tumour was left behind. Long term support for hearing loss, tinnitus and balance problems can be provided by your local audiology team.
Recovery
Everyone recovers at a different speed. It is normal to feel very tired for several weeks after surgery. It helps to rest and slowly increase your activity over time. Many people need between three and six months off work to recover fully. If you have questions while you recover, the specialist nurse team can support you.
Further support
British Acoustic Neuroma Association
Website: BANA UK | British Acoustic Neuroma Association
Phone: 01246550011
Email: admin@bana-uk.com
Brain Tumour Support
Website: Home - Brain Tumour Support
General enquiries: 01454 414 355
Support Services line: 01454 422 701
Support email: support@braintumoursupport.co.uk
Information email: info@braintumoursupport.co.uk
Facial Palsy UK
Website: Facial Palsy UK - Supporting people affected by facial paralysis
Enquiries: 0300 030 9333
Email: info@facialpalsy.org.uk
Hearing Link
Website: Hearing Link Services | Hearing Dogs for Deaf People
Phone: 01844 348111
Email: enquiries@hearinglink.org
Action for Hearing Loss
Website: RNID - National hearing loss charity
Phone: 0808 808 0123
SMS: 07360 268 988
Email: contact@rnid.org.uk
Brain Trust
Website: Home - Brainstrust, brain tumour charity
Phone: 01983 292 405
Email: hello@brainstrust.org.uk
Brain Tumour Charity
Website: The Brain Tumour Charity | Research - Support - Campaigning
Phone: 0808 800 0004
Contact: Contact us | The Brain Tumour Charity
Tinnitus UK
Website: Home - Tinnitus UK
Phone: 0800 0180 527
Email: helpline@tinnitus.org.uk
Date published: 30 June 2026 Review due: 30 June 2029 PI number: BFT003103
Leech therapy
Introduction
This information aims to answer some of the questions you may have about leech therapy. It explains the benefits, risks and alternatives of the procedure, as well as what to expect.
If you have any questions or concerns, please do not hesitate to speak to one of the team caring for you.
What are leeches and why are they used?
Medicinal leeches are worms that suck and feed on blood. Their scientific name is Hirudo medicinalis and Hirudo verbana.
They have been used in medicine since the dawn of civilization, and recently there has been an increase in using leeches in reconstructive surgery.
Leeches help to improve blood circulation in congested flaps or other tissue (such as an amputated finger that has been re-attached).
How do they work?
They latch to the skin with their tiny sharp teeth and their saliva contains a number of chemicals to aid them to suck and feed on blood. These chemicals include a local anaesthetic (to reduce pain) and blood thinners.
Am I going to feel pain?
Leech bites are typically painless because they have a local anaesthetic in their saliva.
What are the benefits of leeches?
In some cases where blood is congested and needs to be released release, leech therapy can help.
Leeches can suck a large amount of blood relative to their body. Each leech can suck between 5 - 15 millilitres of blood in one feed. The bite mark can still bleed a little for up to 72 hours after the leech has detached, due to the blood thinners in the leech’s saliva which act only locally (on this area). This often resolves the problem with the circulation.
Why was I chosen to be offered leech therapy?
You have been offered leech therapy because we believe it would be the best treatment for your congested flap or other tissue.
If there is not enough outflow of blood in this area and it is left untreated, it may lead to the flap or other tissue dying.
What are the side effects and risks of leeches?
- Leech therapy is often associated with bleeding and commonly transfusion of blood / blood products during or after treatment. We will do blood tests every day to see if you need a blood transfusion. Leech therapy will not be started unless you are comfortable with the possibility of blood transfusion. If you cannot or would not like to have blood transfusion, leech therapy will not be started.
- Leeches contain bacteria that sometimes cause infection. You will be started on an oral antibiotic to prevent this. The leech site will be monitored daily by the nurses and doctors. If you are allergic to any of the antibiotics started, please tell your medical team and you will be offered an alternative antibiotic.
- Rarely, people may develop an allergic reaction to leeches. Leeches will not be used on you if you have any history of allergic reactions to them.
- Leech therapy may not be suitable if you have an immunodeficiency, bleeding disorders, heart problems, unless you and your consultant decide the benefits of using leeches outweighs the risks.
- eeches can sometimes migrate into dressings. Nurses will be closely looking after your leeches when they are used.
- It has been reported that some patients may have some psychological difficulties in dealing with leeches. If that is the case, our psychologists will be happy to offer their advice and help.
- Leeches in our department are never used between patients and are disposed of humanely and safely. Transmission of blood borne diseases is not a risk.
Is there an alternative?
Usually, if your doctor has decided to use leech therapy, it means it is the last resort to save your congested flap. If you choose to do nothing, blood may clot and prevent blood flow to the flap. This may lead to some or all the tissue dying and the flap will need to be removed.
How do I give my consent?
If you agree to go ahead with leech therapy, you will be asked to sign a consent form.
What happens next?
- The nurse will clean the area and apply the leech. Sometimes the nurse will scratch the area to allow the leech to latch on.
- We will closely monitor the leeches and the area to check its response to treatment. The number of leeches used and how often we use them depends on the response.
- You will have daily blood tests.
- After each feed, leeches are disposed of safely and according to trust policy.
What do I need to do?
You will be asked to stay in a position that allows the leech therapy to work.
You will be asked to avoid eating or drinking any caffeine- containing food or drinks (such as tea; coffee or cola) and to avoid the use of nicotine-containing products (such as cigarettes or nicotine replacement therapy), during your hospital stay.
What do I need to be aware of after the leech therapy finishes?
There are no specific aftercare instructions. However, if you feel unwell (for example, if you have a fever, increased redness, or pain in the area) please let the team caring for you know.
Contact us
If you have any questions or concerns about leech therapy, please talk to your clinical team, including your plastic surgeon, plastic clinical nurse specialist, nursing team or pharmacy staff.
You can also speak to the ward sister or nurse in charge of Ward 33A on 0117 414 3100.
Feedback
If you would like to give us any feedback on your care or treatment please see this page Feedback | North Bristol NHS Trust
Further information
- For online information about health visit nhs.uk
- NHS 111 offers medical help and advice from fully trained advisers supported by experienced nurses and paramedics. Available over the phone 24 hours a day.
- References available on request.
© North Bristol NHS Trust. This edition published June 2026. Review due June 2029. NBT002763
Long term azithromycin for adults with respiratory conditions
Azithromycin prophylaxis
Azithromycin is an antibiotic. It can be used for a few days to treat certain infections.
Azithromycin can also be used for a long period (months) to help protect people with some types of lung disease. This leaflet is about long term use of azithromycin for people with lung disease. This is called azithromycin prophylaxis.
Why have I been prescribed long-term azithromycin (azithromycin prophylaxis)?
You have been prescribed long term azithromycin to prevent chest infections and to improve your chest symptoms.
Azithromycin does not work for everyone with lung disease but it may help you in two ways:
- it is an antibiotic and can kill some of the bugs (bacteria) that could cause chest infections
- it can reduce inflammation in the airways so it can help to relieve cough, sputum production, and breathlessness
Azithromycin used in this way, is “off-label” and is different to what described in the patient information leaflet that comes with the medication. Using it like this is endorsed by the British Thoracic Society. It is important to take the medication as your Respiratory Consultant has advised.
What do I need to know before I take azithromycin?
Do not take this medication if you are allergic to azithromycin, any of its ingredients, or any other macraolide antibiotic such as erythromycin or clarithromycin.
To make sure azithromycin is the best choice for you your consultant/respiratory nurse specialist will:
- ask you to provide phlegm samples, to check for non tuberculosis mycobacterium. If this bacteria is present, azithromycin cannot be used
- check your heart’s rhythm using an electrocardiogram (ECG); this is also known as a heart tracing
- take some blood tests and check your liver function before and one month after starting azithromycin
Azithromycin will not work if you are a current smoker. You should have stopped smoking completely before we prescribe it. Azithromycin can also make you more prone to sunburn and we recommend using sun block on hot sunny days or when on holiday. Speak to your doctor or pharmacist to see how we can support you to stop smoking.
How long will I be on this medicine?
Usually for 6 to 12 months. This gives enough time for you and your doctor to see if it works for you. If you get less chest infections or have less cough, sputum production, and breathlessness then it may be useful to stay on it for longer.
What are the common and important side effects?
Most people have no troublesome side effects.
- Some people have tummy upset, feeling sick (nausea), getting sick (vomiting).
- Some people get light headedness, dizziness, or fast heart rate (palpitations) and may need to get their ECG (heart tracing) checked.
- A small number of people get jaundice (yellow colour of the skin or whites of your eyes) or itching because of liver upset.
- A very small number of people get hearing problems (ringing in the ears or poor hearing). If you notice a change in your hearing, it is important you stop the medication and seek medical advice
- A very small number of people get poor balance (unsteady on their feet).
- Some people get diarrhoea caused by overgrowth of a bacteria known as C diff (Clostridioides difficile).
If you think azithromycin is causing you troublesome side effects at any time you should talk to your doctor. You may need to stop taking it.
What dose do I take?
The usual dose of azithromycin is 250mg tablets (one capsule) three times per week; normally taken on a Monday, Wednesday, and Friday. In certain situations, your doctor may prescribe you a higher dose of 500mg. Occasionally, it may be prescribed for you to take every day.
Take your dose 1 hour before food or at least 2 hours after food. Swallow whole with a glass of water.
What if I forget to take my dose?
This should not cause any problems. Take your next dose at the normal time.
Will azithromycin interfere with any other medicines that I am taking?
- Azithromycin can interfere with many other medicines and herbal remedies.
- Tell your doctor or pharmacist if you are taking any other medicines or herbal remedies before you start taking azithromycin.
- Tell your doctor or pharmacist before you star t on any new medicines or herbal remedies while on azithromycin.
- If you are prescribed another antibiotic, check with your doctor whether you should continue to take azithromycin.
What should I do if I have a flare-up of my lung condition?
Although azithromycin is an antibiotic, you may still need to take other antibiotics for any chest infections or flare-ups of your lung condition. You may need to stop your azithromycin when starting a course of antibiotics and your team will advise you.
Can I drink alcohol when taking azithromycin?
Yes, within the government guidance of no more than 14 units of alcohol per week. Azithromycin does not interact with alcohol.
More information
If you have any other questions, please speak to the doctor or nurse who prescribed you the azithromycin.
© North Bristol NHS Trust. This edition published May 2026. Review due May 2029. NBT003626
AAC access methods
Access in AAC means the way a person makes their communication system work. Directly touching a screen with a finger is the easiest way to make a device work, but for people who are unable to do this there are different access methods that can be explored.
Direct touch access
Direct touch access means using your finger to select icons on a touchscreen device, such as a smartphone or tablet. This is a common AAC access method because it is the easiest way to make a selection.
To make touch access easier, the device accessibility settings can be used. For example, press and holding for a set time to select, ignoring accidental touches or making the text bigger.
Some AAC users use a keyguard, which is a thick plastic cover with holes that sits on the screen. Keyguards can help guide your finger to the right place and make it easier to select what you want without errors.
Partner assisted scanning (PAS)
Partner-assisted scanning (also known as PAS) is a communication method that can be used where someone cannot easily point, touch or see their AAC. Instead, a communication partner helps by reading out or pointing to choices, one at a time, in order. When the communication partner gets to the right word or symbol, the person communicates “yes” using their own reliable signal. This might be a sound, a gesture, a blink, or any agreed‑upon response.
Partner‑assisted scanning can be flexible and personalised. It allows the person to take part in conversations even if they cannot use a device directly. The partner works at the person’s pace, giving plenty of time for them to respond.
To see partner-assisted scanning using an alphabet board, watch this video
To see partner-assisted scanning using a communication book, watch this video
Pointer control
Pointer control works like a computer mouse, where the cursor freely moves across the screen of a communication device using tools such as:
- joystick
- trackball
- mouse
- trackpad
- head mouse (allows you to control the cursor by moving your head)
This access method allows AAC users to navigate a communication aid without needing to touch the screen directly. Pointer control tools come in a range of size, shapes and sensitivities, to suit different needs.
Eye pointing
Eye pointing is a communication method where an AAC user uses their eyes to look at objects, pictures, symbols, phrases or letters. Eye pointing can be used for everything from making simple choices, to complex systems that allow someone to generate full sentences. Some examples of eye pointing systems include:
- E-Tran frame
- MegaBee
- Eye-Link
To see someone using an E-Tran frame, watch this video
To someone using a MegaBee, watch this video
Eye gaze
Eye gaze access allows an AAC user to control a device’s cursor using only their eye movements. To do this the eyegaze camera directs an infared light into the AAC user’s eyes. This light is reflected back to the camera, allowing it to calculate exactly where the person is looking at the screen. Choosing an item to select on the screen can be done by waiting (dwelling), blinking or touching a switch.
Different eye gaze cameras suit different people so it can be useful to try a few different options. For some people, eye gaze may not be the most consistently reliable access method, and in these cases an alternative access method may need to be explored.
To see how eye gaze technology works, watch this video
Switch access
A switch is something you press, touch or move near to make an electronic device do something. For example, to turn on a light, control your TV or to access a communication aid. There are many different kinds of switches. They work in different ways, need different amounts of pressure and can be used by different parts of the body. The photo below shows a small selection of switches and examples of how people might use them.
Photo description:
- Ping-pong switch: Only requires light action. Is water and moisture resistant. Ideal for use as a head switch.
- Buddy button with softy top – Durable and highly responsive switch. Gives auditory and tactile feedback with a click on activation. Using a softy top can reduce discomfort and improves tactile feedback.
- Wobble switch – Sprung switch that activates with light touch in any direction.
- Finger mouse – Handheld mouse that can be used as a switch. Also used as a pointer for computer access.
- FingerButton switch – Highly responsive with small activation area and very little force required to activate. Can be wraped around a finger.
- Pal pad switch – Ultra-sensitive and low-profile. Is durable and rigid.
- Puff switch – Can be used hands-free. Use a puff (breath) to activate.
- Pillow switch – Soft and smooth suitable for head or cheek activation.
To use a switch with a communication aid the switch can be used to move the highlight around the screen and then select what you want. To see how this works watch the video below.
Weight Assessment and Management Service (WAMS)
WAMS is a specialist service supporting people living with obesity who are motivated to explore behavioural, medical and/or surgical management of their weight.
We are a friendly team offering support and guidance to help you lose weight and improve your health and wellbeing.
The team includes consultant endocrinologists (medical doctors), dietitians, psychologists, a pharmacist, and office staff.
How does the service work?
WAMS is a 12 month service where you will be offered an assessment appointment followed by a support plan. This will be tailored to you.
As you progress through the service, the team will discuss your care to find the best way to continue supporting you.
Our approach
We hope that you feel respected and valued during your time in our service. We are not here to shame or blame. Our approach is to view obesity as a complex, long-term health condition.
Please be reassured that we would like to hear about what is actually happening in your life, rather than what you think we might want to hear. We are here to listen and help you to achieve the most positive outcomes that you can, and this is only really possible if you feel able to be open and honest about your situation.
What can you expect at your initial assessment?
At your first appointment you will speak with a consultant endocrinologist who will check for any medical causes for obesity and check other medical problems that may need treatment. You may be referred for further tests if considered necessary. These may include: blood tests, CT scans, camera investigations (endoscope).
You will speak to a dietitian to understand your eating habits and explore your relationship with food, both now as well as in the past. We understand this can be difficult, but we encourage you to share what you can so that we can help you as best as possible.
You may also see a psychologist who will ask about your wellbeing and help you to identify how your thoughts and feelings may be affecting your weight. They might make some suggestions to help you with your mood and work towards making changes.
What can you expect after your initial assessment?
After these first meetings, we will agree on a weight management plan for you. Sometimes we will need to signpost people onto other services before we can offer support. This is so that they are ready and able to work on their goals with our team.
Most of our interventions are offered in an online group format, for example:
The Mood and Food programme
A blend of nutrition advice and support with the psychological aspects of eating – jointly run by dietitians and psychologists.
Our Coping with Emotion programme
A space in which to develop coping strategies for emotional eating behaviours – run by the psychology team.
Quotes from people who have attended sessions:
- “The group sessions I have attended have been excellent and very informative.”
- “Positive environment, non-judgemental, non-prescriptive. Lots of really useful advice and tips.”
There is the possibility of 1-1 sessions if the team feel that there are strong reasons for this. These may be online, via the phone, or in-person, depending on the situation.
Medical management of weight
Some people may be able to have medication to support weight loss. When available, this will be prescribed in line with local and National Institute for Health and Care Excellence (NICE) guidelines.
People who are being prescribed medication for weight management by our team are able to receive this support for up to two years.
Bariatric surgery (‘weight loss surgery’)
We work closely with members of the bariatric surgery service which is made up of surgeons, dietitians, psychologists and a nurse specialist.
Some people in the weight management service are interested in bariatric surgery, others are not, and some people are unable to have it for various reasons.
It is normal for people to need support and preparation to make sure that they are ready for surgery. Our aim is to prepare people for the significant dietary and psychological changes which are required for surgery to be effective and safe.
Please note that completing your weight management plan in the WAMS service does not necessarily guarantee that you would be eligible for bariatric surgery.
It is our policy that people who miss appointments without giving any notice, or cancel more than two consecutive appointments, may be discharged back to the care of their GP.
© North Bristol NHS Trust. This edition published May 2026. Review due May 2029. NBT002960.
Test Information
This is a searchable database of information about tests offered by Severn Pathology. You can browse the index, enter a test name, part of a test name, abbreviation or clinical indication below.
Information available depends on the type of assay and department, but generally consists of alternative names, clinical indications, patient preparation (where appropriate), special precautions, department responsible for the test and reference ranges (where applicable).
The containers listed refer to those used to collect samples from adults locally in GP practices and hospital wards/outpatients. Details of the containers used for neonates, children and in the emergency zone (ED, AAU, ITU) can be found here Tube Guide and Recommended Order of Draw.
You may also find Lab Tests Online UK useful an additional resource for help you understand the many clinical laboratory tests that are used in diagnosis, monitoring and treatment of disease.
| Special notes | Tube type | Sample type | Test name | Ideal volume | Turnaround time | Discipline |
|---|---|---|---|---|---|---|
|
24 | Serum | 1,25-Dihydroxy Vitamin D | 5 mL | 4 weeks | Clinical Biochemistry |
|
24 | Serum | 11-deoxycortisol | 1 mL | 1 week | Clinical Biochemistry |
|
20 | Plasma | 17 OHP | 5 mL | 14 days | Clinical Biochemistry |
|
31 | Blood spot | 17 OHP | see notes | 14 days | Clinical Biochemistry |
|
17 | Plasma (fluoride oxalate) | 3-Hydroxybutyrate | 5 mL | 7 days | Clinical Biochemistry |
| 24 | Serum | 5-Alpha Dihydrotestosterone | 1 mL | 28 days | Clinical Biochemistry | |
|
5 | Urine - 24 hour | 5-HIAA | n/a | 7 days | Clinical Biochemistry |
|
20 | Plasma | 7-dehydrocholesterol | 2 mL | 28 days | Clinical Biochemistry |
| 34 | CSF | ACE | 500 uL | 6 weeks | Clinical Biochemistry | |
| 24 | Serum | ACE | 5 mL | 7 days | Clinical Biochemistry | |
| 24 | Serum | Acetylcholine Receptor Antibody | 2 mL | 3 weeks | Immunology | |
|
24 | Serum | Aciclovir/CMMG | <3 days | Antimicrobial Reference Laboratory | |
|
14 | Plasma | ACTH | 5 mL | 5 days | Clinical Biochemistry |
| 24 | Serum | Active B12/HoloTC | 1 mL | 7 days | Clinical Biochemistry | |
| 20 | Plasma | Acylcarnitines | 2 mL | 21 days | Clinical Biochemistry | |
| 9 | Blood spot | Acylcarnitines | 1x Spot | 21 days | Clinical Biochemistry | |
|
13 | Plasma | ADAMTS13 | Urgent requests: 24 hours; Routine requests: 2 weeks. | Haematology | |
|
34 | Fluid | Adenosine Deaminase in TB | 1 mL | 14 days | Clinical Biochemistry |
| 43 | Swabs (nose and throat) | Adenovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Adenovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Adenovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 11 | Faecal sample | Adenovirus PCR |
pea sized amount | 2 days | Microbiology | |
| 43 | Swab (eye) | Adenovirus (qualitative) PCR (In house) |
0.5 | 4 days | Virology | |
| 14 | EDTA Blood sample | Adenovirus (quantitative) PCR (In house) |
0.45 | 3 days | Virology | |
| 24 | Serum | Adrenal Cortex Antibody | 2 mL | 14 working days | Immunology | |
| 24 | Serum | AFP | 5 mL | 1 day | Clinical Biochemistry | |
| 34 | CSF | AFP | 2 mL | 3 days | Clinical Biochemistry | |
| 24 | Fluid | Albumin | 5 mL | 3 days | Clinical Biochemistry | |
| 24 | Serum | Albumin | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 35 | Urine - Random | Albumin / creatinine ratio | n/a | 1 day | Clinical Biochemistry | |
|
14 | Plasma | Aldosterone | 5 mL | 21 days | Clinical Biochemistry |
| 24 | Serum | Alk Phos Isoenzymes | 5 mL | 7 days | Immunology | |
| 24 | Serum | Allergen specific IgE | 2 mL | 7 working days | Immunology | |
| 24 | Serum | ALP | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | Alpha 1 antitrypsin activity | 5 mL | 3 days | Immunology | |
| 24 | Serum | Alpha 1 antitrypsin phenotype | 5 mL | 14 working days | Immunology | |
| 24 | Serum | Alpha subunit | 2 mL | 5 weeks | Clinical Biochemistry | |
| 24 | Serum | ALT | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
10 | Whole Blood | Aluminium | 5 mL | 7 days | Clinical Biochemistry |
| 24 | Serum | AMH | 2 mL | 1 week | Clinical Biochemistry | |
|
24 | Serum | Amikacin | <1 day | Antimicrobial Reference Laboratory | |
|
34 | CSF | Amino Acids CSF | 1 mL | 14 days | Clinical Biochemistry |
| 20 | Plasma | Amino Acids Plasma | 2 mL | 21 days | Clinical Biochemistry | |
| 35 | Urine - Random | Amino Acids Urine | 5 mL | 21 days | Clinical Biochemistry | |
|
14 | Plasma | Amiodarone | 5 mL | 7 days | Clinical Biochemistry |
|
14 | Plasma | Ammonia | 1 mL | 2 hours | Clinical Biochemistry |
| 24 | Fluid | Amylase | 5 mL | 3 days | Clinical Biochemistry | |
|
35 | Urine - Random | Amylase | 5 mL | 4 hours | Clinical Biochemistry |
| 24 | Serum | ANCA | 2 mL | 4 working days | Immunology | |
| 24 | Serum | Androstenedione | 5 mL | 28 days | Clinical Biochemistry | |
| 24 | Serum | Anion Gap | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 16 | Whole Blood | Antenatal Blood Group and Antibody Screen | 4 mL | 1 day | Blood Transfusion | |
| 24 | Clotted blood sample | Antenatal Screen - HBsAg, HIV and Syphilis Serology | 0.5 | 3 days | Virology | |
| 24 | Serum | Anti Cardiolipin Antibody | 2ml | 1 week | Immunology | |
| 24 | Serum | Anti PLA2 R | 2ml | 2 weeks | Immunology | |
| 13 | Whole Blood | Anti Thrombin | 3 full tubes | 21 days | Haematology | |
| 13 | Plasma | Anti-Xa | 2.7 mL | 4 hours for UFH, 24 hours for all other tests. If result is required more urgently than 24 hours, please contact haematology laboratory and testing will be expedited if possible. | Haematology | |
|
16 | Whole Blood | ANTIBODY Investigation (red cells) | 6ml x 2 | Up to 72 hours | Blood Transfusion |
| 35 | Urine | Antihypertensive Drug Assay | 5mL random | 2 weeks | Clinical Biochemistry | |
| 24 | Serum | Antinuclear Antibody | 2 mL | 4 working days | Immunology | |
|
14 | Whole Blood | Apo E genotyping | 4 mL | 28 days | Genetics |
| 24 | Serum | Apolipoprotein B | 1 mL | 1 week | Clinical Biochemistry | |
| 13 | Whole Blood | APTT/APTT-R | 2.7 mL | 24 hours | Haematology | |
|
14 | Whole blood | Arsenic | 2 mL | 2 weeks | Clinical Biochemistry |
|
34 | Urine | Arsenic (urine) | 5 mL | 2 weeks | Clinical Biochemistry |
|
25 | Fluid | Asialotransferrin | see notes | 3 working days | Immunology |
| 24 | Clotted blood samples | Aspergillus Antigen | 700µL | Mean 1 day | Mycology Reference Laboratory | |
| 34 | Broncheolar lavage (BAL) samples | Aspergillus Antigen | 700µL | Mean 1 day | Mycology Reference Laboratory | |
| 34 | Broncheolar lavage (BAL) samples | Aspergillus Antigen | 700µL | Mean 1 day | Mycology Reference Laboratory | |
| 24 | Clotted blood samples | Aspergillus Antigen | 700µL | Mean 1 day | Mycology Reference Laboratory | |
| 24 | serum | Aspergillus IgG | 2ml | 1 week | Immunology | |
| 24 | Clotted blood samples | Aspergillus Precipitins | 200µL | Mean 3 days | Mycology Reference Laboratory | |
| 24 | Clotted blood samples | Aspergillus Precipitins | 200µL | Mean 3 days | Mycology Reference Laboratory | |
|
24 | Serum | AST | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry |
| 11 | Faecal sample | Astrovirus PCR |
pea sized amount | 2 days | Microbiology | |
| 24 | Serum | Autoimmune Liver Disease Antibodies | 2 mL | 4 working days | Immunology | |
| 43 | Swabs (nose and throat) | Avian Influenza A PCR Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 24 | Serum | Avian proteins IgG | 2ml | 1 week | Immunology | |
| 34 | BAL MCS | BAL MCS | 3 mL | 12 days | Microbiology | |
|
35 | Urine - Random | Barbiturates | 5 mL | 3 days | Clinical Biochemistry |
|
24 | Serum | Benzylpenicillin (Penicillin G) | <3 days | Antimicrobial Reference Laboratory | |
| 24 | Serum | Beta 2 Glycoprotein 1 | 2 mL | 7 working days | Immunology | |
| 24 | Serum | Beta 2 microglobulin | 2 mL | 7 working days | Immunology | |
| 24 | Clotted blood samples | Beta D Glucan | 200µL | Mean <1 day | Mycology Reference Laboratory | |
| 24 | Clotted blood samples | Beta D Glucan | 200µL | Mean <1 day | Mycology Reference Laboratory | |
| 24 | Serum | Bicarbonate | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | Bilirubin | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
Plasma | Bilirubin - infants | 1 full paediatric lithium heparin tube | 4 hours | Clinical Biochemistry | |
| 24 | Serum | Bilirubin-(Conjugated fraction) | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
9 | Blood spot | Biopterins | 6x Spots | 28 days | Clinical Biochemistry |
|
14 | Plasma | Biotinidase | 1 mL | 7 days | Clinical Biochemistry |
| 34 | Urine | BK virus (quantitative) PCR (In house) |
0.5 | 3 days | Virology | |
| 14 | EDTA Blood sample | BK virus (quantitative) PCR (In house) |
0.45 | 3 days | Virology | |
|
14 | Whole Blood | Blood Film | 24 hours | Haematology | |
|
18 | Whole Blood | Blood Gases | see notes | n/a | Clinical Biochemistry |
|
Bone Marrow | Bone Marrow Aspirate or Trephine | Haematology | |||
| 24 | Serum | Bone profile | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 43 | Pernasal swabs | Bordetella parapertussis Molecular assay (NAAT) |
0.5 | 3 days | Virology | |
| 43 | Pernasal swabs | Bordetella pertussis Molecular assay (NAAT) |
0.5 | 3 days | Virology | |
| 24 | Clotted blood sample | Bordetella pertussis antibodies IgG |
0.17 | 5 days | Virology | |
| 24 | Clotted blood sample | Borrelia burgdorferi (Lyme) antibodies IgG and IgM |
0.38 | 4 days | Virology | |
|
28 | Urine - Random | C-peptide : creatinine ratio | 2 mL | 1 week | Clinical Biochemistry |
| 14 | Plasma | C-Peptide (plasma) | 5ml | 1 week | Clinical Biochemistry | |
| 11 | Faeces | C.difficile toxin | Pot should be at least 1/3 full | 24 hours | Microbiology | |
|
24 | Serum | C1 Esterase Inhibitor | 2 mL | 14 working days | Immunology |
|
14 | Whole Blood | C3 Degradation Products | 3 mL | 5 working days | Immunology |
| 24 | Serum | C3 Nephritic Factor | 2 mL | 7 working days | Immunology | |
| 24 | Serum | CA 125 | 5 mL | 1 day | Clinical Biochemistry | |
| 24 | Serum | CA 15-3 | 5 mL | 1 day | Clinical Biochemistry | |
| 24 | Serum | CA 19-9 | 5 mL | 1 day | Clinical Biochemistry | |
|
35 | Urine - Random | Cadmium | 5 mL | 14 days | Clinical Biochemistry |
|
14 | Whole Blood | Cadmium | 4 mL | 14 days | Clinical Biochemistry |
|
24 | Serum | Caeruloplasmin | 5 mL | 4 days | Clinical Biochemistry |
|
24 | Serum | Calcitonin | 5 mL | 14 days | Clinical Biochemistry |
| 24 | Serum | Calcium | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 4 | Urine - 24 hour | Calcium | n/a | 3 days | Clinical Biochemistry | |
|
27 | Serum and Urine | Calcium excretion index | 5 mL | 3 days | Clinical Biochemistry |
| 11 | Faeces | Calprotectin | 5 g | 7 working days | Immunology | |
| 24 | Clotted blood samples | Candida Antigen | 300µL | Mean 1.6 days | Mycology Reference Laboratory | |
| 35 | Urine - Random | Cannabinoids | 5 mL | 3 days | Clinical Biochemistry | |
|
24 | Serum | Carbamazepine | 5 mL | 1 day | Clinical Biochemistry |
|
18 | Whole Blood | Carboxyhaemoglobin | full tube | n/a | Clinical Biochemistry |
| 24 | Serum | Cardiac Muscle Antibody | 2 mL | 21 working days | Immunology | |
|
35 | Urine - Random | Carnitine, | 5 mL | 14 days | Clinical Biochemistry |
| Urine - 24 hour | Catecholamines | |||||
| 14 | Whole Blood | CD 4 Counts | 3 mL | 1 working day | Immunology | |
|
24 | Serum | CDT | 5 mL | 14 days | Clinical Biochemistry |
| 24 | Serum | CEA | 5 mL | 4 days (due to batching of the assay) | Clinical Biochemistry | |
| 24 | Serum | Centromere Antibody | 2 mL | 7 working days | Immunology | |
| 38 | Aptima Urine | Chlamydia trachomatis NAAT |
1 tube | 3 days | Virology | |
| 1 | Aptima Swab | Chlamydia trachomatis NAAT |
1 tube | 3 days | Virology | |
| 24 | Clotted blood sample | Chlamydia trachomatis antibodies IgG |
0.17 | 4 days | Virology | |
| 1 | Swab (eye) | Chlamydia trachomatis/Neisseria gonorrhoeae NAAT |
1 tube | 3 days | Virology | |
| 37 | See Notes | Chlamydia/ GC other swabs | n/a | 10 days | Microbiology | |
| 38 | Urine - Random | Chlamydia/ GC urine | n/a | 10 days | Microbiology | |
| 1 | See Notes | Chlamydia/ GC vaginal swabs | n/a | 10 days | Microbiology | |
|
24 | Serum | Chloramphenicol | <3 days | Antimicrobial Reference Laboratory | |
| 24 | Serum | Chloride | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 20 | Plasma | Cholestanol | 1 mL | 21 days | Clinical Biochemistry | |
| 24 | Serum | Cholesterol | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Fluid | Cholesterol | 2 mL | 3 days | Clinical Biochemistry | |
| 14 | Whole Blood | Cholinesterase Genotype | 4 mL | 10 - 12 weeks | Clinical Biochemistry | |
| 14 | EDTA (whole blood) | Cholinesterase Studies | 5 mL | 3 - 4 weeks | Clinical Biochemistry | |
|
14 | Whole Blood | Chromium | 4 mL | 14 days | Clinical Biochemistry |
|
14 | Plasma | Chromogranin A | 5 mL | 21 days | Clinical Biochemistry |
|
24 | Serum | Ciprofloxacin | <3 days | Antimicrobial Reference Laboratory | |
|
4 | Urine - 24 hour | Citrate | n/a | 7 days | Clinical Biochemistry |
| 20 | Plasma | Citrulline | 1 mL | Clinical Biochemistry | ||
| 24 | Serum | CK | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 13 | Whole Blood | Clauss Fibrinogen | 2.7 mL | 24 hours | Haematology | |
| 13 | Whole Blood | Clotting Screen | 2.7 mL | 24 hours | Haematology | |
| 14 | Plasma | Clozapine Level | 2.7 mL | 10 days | ||
| 34 | Urine | CMV PCR (In house) |
0.5 | 3 days | Virology | |
| 24 | Clotted blood sample | CMV IgG | CMV IgG and IgM 0.190, CMV IgG 0.17 | 4 days | Virology | |
| 24 | Clotted blood sample | CMV IgM | CMV IgG and IgM 0.19, CMV IgM 0.17 | 4 days | Virology | |
|
14 | Whole Blood | Cobalt | 4 mL | 14 days | Clinical Biochemistry |
|
24 | Serum | Colistin | <3 days |
Antimicrobial Reference Laboratory | |
| 24 | Serum | Complement C3 + C4 | 2 mL | 4 working days | Immunology | |
|
24 | Serum | Complement Function | 5 mL | 28 working days | Immunology |
|
24 | Serum | Copeptin | 5 mL | 14 days | Clinical Biochemistry |
| 24 | Serum | Copper | 5 mL | 7 days | Clinical Biochemistry | |
| 5 | Urine - 24 hour | Copper | n/a | 7 days | Clinical Biochemistry | |
| 24 | Serum | Cortisol | 5 mL | 1 day | Clinical Biochemistry | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | COVID-19 Molecular assay (NAAT) |
0.5 | 1 day | Virology | |
| 43 | Swabs (nose and throat) | COVID-19 Molecular assay (NAAT) |
0.5 | 1 day | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | COVID-19 Molecular assay (NAAT) |
0.5 | 1 day | Virology | |
|
35 | Urine - Random | Creatine Studies | 5 mL | 14 days | Clinical Biochemistry |
| 20 | Plasma | Creatine Studies | 2 mL | 21 days | Clinical Biochemistry | |
| 24 | Serum | Creatinine | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 34 | Dialysate | Creatinine | 2 mL | 1 day | Clinical Biochemistry | |
| 24 | Fluid | Creatinine | 2 mL | 3 days | Clinical Biochemistry | |
|
26 | Serum and Urine | Creatinine clearance | n/a | 8 hours | Clinical Biochemistry |
| 24 | Serum | Crithidia for dsDNA antibodies | 2ml | 14 working days | Immunology | |
|
0 | Whole Blood | Crossmatch - (Lymphocyte) for Renal Transplantation Immunology | see "sample required" | Live donor typing and crossmatch = 28 working days | Immunology |
|
16 | Whole Blood | Crossmatch - Blood Transfusion | 4 mL | See Notes | Blood Transfusion |
| 24 | Serum | CRP | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
24 | Serum | Cryoglobulin | Discuss with Laboratory | 10 working days | Immunology |
|
CSF | CSF neurodegenerative markers | 0.5mL in each tube | 10 working days | Clinical Biochemistry | |
|
14 | Plasma | CTx | 2 mL | 21 days | Clinical Biochemistry |
| 24 | Serum | Cyclic Citrullinated Peptide Antibodies | 2 mL | 14 Working days | Immunology | |
|
24 | Serum | Cycloserine | <3 days | Antimicrobial Reference Laboratory | |
|
14 | Whole Blood | Cyclosporin | 4 mL | 3 days | Clinical Biochemistry |
| 24 | Serum | Cystatin C | 2mL | 7 days | Clinical Biochemistry | |
|
4 | Urine - 24 hour | Cystine 24 hour excretion | n/a | 21 days | Clinical Biochemistry |
|
33 | Urine - timed | Cystine day/night | n/a | 21 days | Clinical Biochemistry |
| 35 | Urine - Random | Cystine Random Urine | 5 mL | 21 days | Clinical Biochemistry | |
| 34 | CSF | Cytomegalovirus CMV (quantitative) PCR (In house) |
0.2 | 3 days | Virology | |
| 34 | Amniotic fluid | Cytomegalovirus CMV (quantitative) PCR (In house) |
0.2 | 3 days | Virology | |
| 14 | EDTA Blood sample | Cytomegalovirus CMV (quantitative) PCR (In house) |
0.45 | 3 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Cytomegalovirus CMV(qualitative) PCR (In house) |
0.5 | 3 days | Virology | |
| 24 | Clotted blood sample | Cytomegalovirus IgG avidity | 0.17 | 4 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Cytomegaloviurs CMV (qualitative) PCR (In house) |
0.5 | 3 days | Virology | |
| 13 | Whole Blood | D-Dimer | 2.7 mL | 24 hours | Haematology | |
|
24 | Serum | Daptomycin | <3 days | Antimicrobial Reference Laboratory | |
| 14 | Whole Blood | DAT | 3 mL | 24 hours | Blood Transfusion | |
|
24 | Serum | DHEAS | 5 mL | 10 days | Clinical Biochemistry |
| 24 | Serum | Diabetes Autoantibodies (ZnT8, GAD, IA2) | 2 mL | 28 working days | Immunology | |
|
24 | Serum | Digoxin | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry |
| 24 | Serum | Down's Syndrome Screening | 5 mL | 7 days | Clinical Biochemistry | |
| 14 | Whole Blood | DQ6(DQB1*06:02) | 3 mL | 14 working days | Immunology | |
|
35 | Urine - Random | Drug (Overdose) Screen | 5 mL | 3 days | Clinical Biochemistry |
| 35 | Urine - Random | Drugs of Abuse | 5 mL | 4 days | Clinical Biochemistry | |
| 24 | Serum | ds-DNA antibodies | 2 mL | 7 working days | Immunology | |
| 14 | EDTA Blood sample | EBV (quantitative) PCR (In house) |
0.45 | 3 days | Virology | |
| 24 | Serum | eGFR | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Fluid | Electrolytes | 2 mL | 3 days | Clinical Biochemistry | |
| 24 | Serum | ELF | 5 mL | 10 days | Clinical Biochemistry | |
| 24 | Serum | Endomysium Antibody | 2 mL | Immunology | ||
| 14 | EDTA Blood sample | Enterovirus PCR (In house) |
0.45 | 3 days | Virology | |
| 34 | Vesicle fluid | Enterovirus PCR (In house) |
0.5 | 3 days | Virology | |
| 43 | Swabs Throat swab | Enterovirus PCR (In house) |
0.5 | 3 days | Virology | |
| 43 | Vesicle swab | Enterovirus PCR (In house) |
0.5 | 4 days | Virology | |
| 34 | CSF | Enterovirus PCR (In house) |
0.2 | 3 days | Virology | |
| 43 | Vesicle Swab | Enterovirus PCR (In house) |
0.5 | 4 days | Virology | |
| 11 | Faecal sample | Enterovirus PCR (In house) |
pea sized amount | 3 days | Virology | |
| 24 | Whole Blood | EPO | 5 mL | 10 days | Clinical Biochemistry | |
| 24 | Clotted blood sample | Epstein Barr Virus (EBV) IgG | 0.17 | 4 days | Virology | |
| 24 | Clotted blood sample | Epstein Barr Virus (EBV) serology EBNA VCA IgG and IgM |
0.42 | 4 days | Virology | |
| 34 | CSF | Epstein Barr Virus EBV (qualitative) PCR (In house) |
0.2 | 3 days | Virology | |
|
24 | Serum | Ethambutol | <3 days |
Antimicrobial Reference Laboratory | |
| 35 | Urine - Random | Ethanol | 2 mL | 1 day | Clinical Biochemistry | |
|
17 | Plasma | Ethanol | 5 mL | 4 hours | Clinical Biochemistry |
|
17 | Plasma | Ethylene glycol | 5 mL | 1 day | Clinical Biochemistry |
| 24 | Serum | Extractable Nuclear Antigen | 2 mL | 7 working days | Immunology | |
|
14 | Whole Blood | Fabry Screen | 4 mL | 2-3 weeks | Clinical Biochemistry |
| 13 | Plasma | Factor II | 2 full tubes | 2 weeks | Haematology | |
| 13 | Whole Blood | Factor IX Assay | 2.7 mL | 10 days | Haematology | |
| 13 | Plasma | Factor V | 2 full tubes | 2 weeks | Haematology | |
| 13 | Whole Blood | Factor V Leiden | 2.7 mL | 1 month | Haematology | |
| 13 | Plasma | Factor VII | 2 full tubes | 2 weeks | Haematology | |
| 13 | Whole Blood | Factor VIII Assay | 2.7 mL | 10 days | Haematology | |
|
13 | Plasma | Factor VIII Inhibitor | 2 full tubes | 2 weeks, urgents will be processed as required following discussion with Haematologist | Haematology |
| 13 | Plasma | Factor X | 2 full tubes | 10 days | Haematology | |
| 13 | Plasma | Factor XI | 2 full tubes | 10 days | Haematology | |
| 13 | Plasma | Factor XII | 2 full tubes | 10 days | Haematology | |
| 13 | Plasma | Factor XIII | 2 full tubes | 10 days | Haematology | |
| 11 | Faeces | Faecal Elastase | 5 g | 16 working days | Immunology | |
| Faecal reducing substances | ||||||
| Fat Globules | ||||||
| 24 | Serum | Ferritin | 5 mL | 24 hours | Clinical Biochemistry | |
|
14 | Plasma | FGF-23 | 2 mL | 4 weeks | Clinical Biochemistry |
| 24 | Plasma AND Serum | FIB-4 | 5 mL | 24 hours | Clinical Biochemistry | |
| Faecal | FIT | 2 working days | Immunology | |||
|
24 | Serum | Flucloxacillin | <3 days | Antimicrobial Reference Laboratory | |
|
Serum | Fluconazole | < 2 days | Antimicrobial Reference Laboratory | ||
|
Serum | Flucytosine | < 2 days | Antimicrobial Reference Laboratory | ||
|
16 | Whole Blood | Foetal leak investigation | 4 mL | 1 day | Blood Transfusion |
| 24 | Serum | Folate | 5 mL | 24 hours | Clinical Biochemistry | |
| 24 | Serum | Free androgen index | 5 mL | 7 days | Clinical Biochemistry | |
|
17 | Plasma (fluoride oxalate) | Free Fatty Acids | 2 mL | 7 days | Clinical Biochemistry |
| 16 | Whole Blood | Free fetal DNA for fetal Rh typing | 4 mL | 15 days | Blood Transfusion | |
|
24 | Serum | Free Light Chains | 2 mL | 7 working days | Immunology |
|
24 | Serum | Free Testosterone | 5 mL | 7 days | Clinical Biochemistry |
|
24 | Serum | Fructosamine | 5 mL | 7 days | Clinical Biochemistry |
| 24 | Serum | FSH | 5 mL | 1 day | Clinical Biochemistry | |
| 14 | Whole Blood | Full Blood Count | 4 mL | 24 hours | Haematology | |
| 35 | Urine - Random | Galactitol | 5 mL | 28 days | Clinical Biochemistry | |
|
20 | Whole Blood | Galactokinase | 1 mL | 14 days | Clinical Biochemistry |
|
20 | Whole Blood | Galactosaemia screen | 1 mL | 7 days | Clinical Biochemistry |
|
20 | Whole Blood | Galactose-1-phosphate | 0.5 mL | 28 days | Clinical Biochemistry |
|
20 | Whole Blood | Galactose-1-phosphate uridyl transferase (quantitative) | 1 mL | 28 days | Clinical Biochemistry |
| 24 | Serum | Gamma GT | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
24 | Serum | Ganciclovir | <3 days | Antimicrobial Reference Laboratory | |
| 24 | Serum | Ganglioside Antibodies | 2 mL | 21 working days | Immunology | |
| 24 | Serum | Gastric Parietal Cell Antibody | 2 mL | 4 working days | Immunology | |
|
14 | Plasma | Gastrin | 5 mL | 28 days | Clinical Biochemistry |
| 24 | Serum | GBM Antibody | 2 mL | 7 working days | Immunology | |
|
24 | Serum | Gentamicin | 5mL | Hospital patients 4 hours | Clinical Biochemistry |
|
14 | Plasma | Glucagon | 5 mL | 28 days | Clinical Biochemistry |
| 17 | CSF | Glucose | 2 mL | 4 hours | Clinical Biochemistry | |
| 17 | Fluid | Glucose | 2 mL | 3 days | Clinical Biochemistry | |
| 24 | Serum | Glucose (inpatients only) | 5 mL | 4 hours | Clinical Biochemistry | |
| 17 | Plasma | Glucose (outpatients/General practice) | 2 mL | 1 day | Clinical Biochemistry | |
| 14 | Whole Blood | Glucose 6 Phosphate Dehydrogenase | 4 mL | 5 working days, 10 working days if sent to referral laboratory for quantitative testing | Haematology | |
| 17 | Plasma | Glucose tolerance test | 2 mL | 8 hours | Clinical Biochemistry | |
| 17 | Plasma | Glucose tolerance test in Pregnancy | 2 mL | 1 day | Clinical Biochemistry | |
| 16 | Whole Blood | Group and Hold | 4 mL | 24 hours | Blood Transfusion | |
|
24 | Serum | Growth Hormone | 5 mL | 7 days | Clinical Biochemistry |
|
14 | Plasma | Gut Hormones | 10 mL | 28 days | Clinical Biochemistry |
| 11 | Faeces | H.pylori | 1/3 full/10ml minimum | 3 days | Microbiology | |
| 14 | Whole Blood | Haematocrit | 4 mL | 24 hours | Haematology | |
| 14 | Whole Blood | Haemoglobin | 4 mL | 24 hours | Haematology | |
| 14 | Whole Blood | Haemoglobinopathy screen | 4 mL | 3 days | Haematology | |
| 24 | Serum | Haemophilus B Antibodies (HIB) | 2 mL | 14 days | Immunology | |
| 34 | Urine - Random and Bone Marrow | Haemosiderin | 2 mL | 7 days | Haematology | |
| 24 | Serum | Haptoglobin | 5 mL | 7 working days | Clinical Biochemistry | |
| 14 | Whole Blood | HbA1c | 4 mL | 3 working days | Haematology | |
| 34 | CSF | hCG | 2 mL | 3 days | Clinical Biochemistry | |
| 24 | Serum | hCG | 5 mL | 1 day (2 hours for urgent requests) | Clinical Biochemistry | |
| See Notes | hCG (Molar) | Clinical Biochemistry | ||||
| 24 | Serum | HDL Cholesterol | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Clotted blood sample | Helicobacter pylori antibodies IgG |
0.16 | 4 days | Virology | |
| 24 | Clotted blood sample | Hepatitis A IgM and IgG |
Anti-HAV 0.24 HAVIgM 0.17 | 3 days | Virology | |
| 14 | EDTA Blood sample | Hepatitis B (quantitative) Molecular assay |
1mL | 5 days | Virology | |
| 24 | Clotted blood sample | Hepatitis B Surface Antibody Anti-HBs (Quantitative) | 0.3 | 3 days | Virology | |
| 24 | Clotted blood sample | Hepatitis B Surface Antigen (HBsAG) | 0.5 | 3 days - Screen 7 days - Confirmations | Virology | |
| 14 | EDTA Blood sample | Hepatitis C (genotype) PCR (In house) |
0.2 | 14 days | Virology | |
| 14 | EDTA Blood sample | Hepatitis C (quantitative) PCR (In house) |
1mL | 5 days | Virology | |
| 24 | Clotted blood sample | Hepatitis C antibody Total antibody screening & confirmation testing |
0.5 | 3 days - Screen 7 days - Confirmations | Virology | |
| 24 | Clotted blood sample | Hepatitis E IgM & IgG |
0.5 | 4 days | Virology | |
| 24 | Clotted blood sample | Hepatits B core antibody | 0.26 | 3 days | Virology | |
| 34 | CSF | Herpes Simplex HSV 1 and 2 PCR (In house) |
0.2 | 3 days | Virology | |
| 43 | Vesicle Swab | Herpes simplex HSV 1 and 2 PCR (In house) |
0.5 | 4 days | Virology | |
| 43 | Swab (eye) | Herpes simplex HSV 1 and 2 PCR (In house) |
0.5 | 4 days | Virology | |
| 24 | Clotted blood samples | Herpes Simplex HSV 1 and 2 specific serology IgG |
0.19 | 4 days | Virology | |
| 14 | EDTA blood sample | Herpes Simplex HSV 1and 2 PCR (In house) |
0.45 | 3 days | Virology | |
| 14 | EDTA (whole blood) | HGA - HFE Gene Analysis | 1-5 ml | Genetics (Exeter lab) | ||
| 14 | EDTA Blood sample | HHV6 - Blood PCR (In house) |
0.45 | 3 days | Virology | |
| 34 | CSF | HHV6 - CSF PCR |
0.45 | 3 days | Virology | |
| 24 | Serum | Histone antibodies | 2 mL | 21 working days | Immunology | |
|
24 | Serum | HIT | 1 day for urgent requests, otherwise 5 days. | Haematology | |
| 14 | EDTA Blood sample | HIV (quantitative) Molecular assay |
1mL | 7 days | Virology | |
| 24 | Clotted blood sample | HIV 1 and 2 antigen/antibody Confirmation |
0.5 | 7 days - Confirmations | Virology | |
| 24 | Clotted blood sample | HIV 1 and 2 antigen/antibody Total antibody/antigen |
0.35 | 3 days - Screen 4 days - confirmations | Virology | |
| 24 | Serum | HLA antibody screen | 8 mL | 14 working days | Immunology | |
| 15 | Whole Blood | HLA type (DR,DQ,DP)Class II | 8 mL | 28 working days | Immunology | |
| 15 | Whole Blood | HLA type(A,B,C)Class I | 8 mL | 28 working days | Immunology | |
| 14 | Whole Blood | HLA-A29 | 3 mL | 14 working days | Immunology | |
| 14 | Whole Blood | HLA-B27 | 3 mL | 14 working days | Immunology | |
| 14 | Whole Blood | HLA-B51(5) | 3 mL | 14 working days | Immunology | |
| 14 | Whole Blood | HLA-B57(B*57:01) | 3 mL | 10 working days | Immunology | |
| 14 | Whole Blood | HLA-DQ2+DQ8(3) | 3 mL | 14 working days | Immunology | |
|
14 | Plasma | Homocysteine (Total) | 2 mL | 7 days | Clinical Biochemistry |
| 24 | Clotted blood sample | HTLV antibody Total Antibody screening |
0.25 | 3 days | Virology | |
| 43 | Swabs (nose and throat) | Human metapneumovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Human metapneumovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Human metapneumovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 35 | Urine - Random | HVA | 5 mL | 7 days | Clinical Biochemistry | |
| 24 | Serum | IgE | 2 mL | 7 working days | Immunology | |
| 24 | Serum | IGF-1 | 5 mL | 5 days | Clinical Biochemistry | |
|
24 | Serum | IGFBP-3 | 5 mL | 14 days | Clinical Biochemistry |
| 24 | Serum | IgG Subclasses | 2 mL | 7 working days | Immunology | |
| 14 | Whole Blood | Immunodeficiency (Immunophenotyping) | 3 mL | 2 working days | Immunology | |
|
n/a | Immunodeficiency Investigations | Immunology | |||
| 24 | Serum | Immunoglobulins | 2 mL | 3 working days | Immunology | |
| 7 | Rectal Swab | Infection screen – VRE | 3 days | Microbiology | ||
| 7 | Various | Infection screen Carbapenemase screen (rectal swab) | n/a | 3 days | Microbiology | |
| Various | Infection screen MRC MRC screen for ESBL-producing Enterobacterales | n/a | 3 days | Microbiology | ||
| Various | Infection screen MRSA Screen | n/a | 2days | Microbiology | ||
| Various | Infection screen MSSA Screening (Renal/ Spinal) | n/a | 3 days | Microbiology | ||
| 7 | Various | Infection screen Pseudomonas Screening (NICU) | n/a | 3 days | Microbiology | |
| 14 | Plasma | Infectious Mononucleosis | 3 mL | 72 hours | Haematology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Influenza A Virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Influenza A Virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Influenza A virus Molecular assay (NAAT) | 0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Influenza B Virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Influenza B virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Influenza B Virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 13 | Whole Blood | INR | 2.7 mL | 24 hours | Haematology | |
|
44 | Plasma | Insulin (Paediatric) | 1 mL | 1 working day | Clinical Biochemistry |
|
24 | Serum | Insulin and C-peptide | 5 mL | 14 days | Clinical Biochemistry |
| 24 | Serum | Insulin Antibodies | 2 mL | 21 working days | Immunology | |
| 24 | Serum | Intrinsic Factor Antibodies | 5 mL | 10 days | Clinical Biochemistry | |
| 24 | Serum | Iohexol GFR | 2ml | 7 days | Clinical Biochemistry | |
| 24 | Serum | Iron | 5 mL | <4 hours | Clinical Biochemistry | |
| 24 | Serum | Iron and Transferrin Saturation | 5 mL | 1 day | Clinical Biochemistry | |
|
Serum | Isavuconazole | < 2 days | Antimicrobial Reference Laboratory | ||
| 17 | Whole Blood Collected in Fluoride Oxalate (Fx) Tube | Isoniazid (+ N-Acetyl-Isoniazid) | 1-2 ml | <3 days (from day of receipt) | Antimicrobial Reference Laboratory | |
|
n/a | Issue of Albumin Solution | n/a | Blood Transfusion | ||
|
n/a | Issue of Fresh Frozen Plasma | n/a | Blood Transfusion | ||
|
n/a | Issue of Platelets | n/a | Blood Transfusion | ||
|
Serum | Itraconazole | < 2 days | Antimicrobial Reference Laboratory | ||
|
35 | Urine - Random | Ketones | 5 mL | n/a | Clinical Biochemistry |
| 17 | CSF | Lactate | 2 mL | 4 hours | Clinical Biochemistry | |
| 17 | Plasma | Lactate (Laboratory analysis) | 2 mL | 4 hours | Clinical Biochemistry | |
|
18 | Whole Blood | Lactate (Point of Care Testing) | n/a | n/a | Clinical Biochemistry |
|
14 | Plasma | Lamotrigine | 5 mL | 1 - 2 weeks | Clinical Biochemistry |
| 34 | CSF | LDH | 0.5 mL | 3 days | Clinical Biochemistry | |
| 24 | Fluid | LDH | 2 mL | 3 days | Clinical Biochemistry | |
| 24 | Serum | LDH | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | LDL Cholesterol | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 35 | Urine - Random | Lead | 5 mL | 7 days | Clinical Biochemistry | |
| 14 | Whole Blood | Lead | 1 mL | 7 days | Clinical Biochemistry | |
| 34 | Urine | Legionella antigen | 1 day | Microbiology | ||
|
34 | Lymph Nodes | Leukaemial/Lymphoma Immunophenotyping | see notes | 1 working day | Immunology |
| 14 | Bone Marrow | Leukaemial/Lymphoma Immunophenotyping | 0.5 mL | 1 working day | Immunology | |
| 14 | Whole Blood | Leukaemial/Lymphoma Immunophenotyping | 3 mL | 1 working day | Immunology | |
|
34 | Other fluids | Leukaemial/Lymphoma Immunophenotyping | see notes | 1 working day | Immunology |
|
20 | Whole Blood | Leukocyte Cystine | 4 mL | 28 days | Clinical Biochemistry |
|
24 | Serum | Levofloxacin | <3 days | Antimicrobial Reference Laboratory | |
| 24 | Serum | LFT | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | LH | 5 mL | 1 day | Clinical Biochemistry | |
|
24 | Serum | Linezolid | <3 days | Antimicrobial Reference Laboratory | |
| 24 | Serum | Lipase | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | Lipid Profile | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
24 | Serum | Lipoprotein (a) | 5 mL | 21 days | Clinical Biochemistry |
| 24 | Serum | Lipoprotein Electrophoresis | 5 mL | 14 days | Clinical Biochemistry | |
|
24 | Serum | Lithium | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry |
| 24 | Serum | Liver Kidney Microsomal | 2 mL | 4 working days | Immunology | |
| 24 | Serum | Liver line blot | 2ml | 2 weeks | Immunology | |
|
13 | Whole Blood | Lupus Anticoagulant | 3 full tubes | 10 days | Haematology |
|
20 | Whole Blood | Lymphocyte Function Tests | 7 mL | 7 working days | Immunology |
|
24 | Serum | Macro CK | 5 mL | 4-6 weeks | Clinical Biochemistry |
| 24 | Serum | Macroprolactin | 5 mL | 14 days | Clinical Biochemistry | |
| 24 | Serum | Macroprolactin confirmation | 2 mL | 3 weeks | Clinical Biochemistry | |
| 4 | Urine - 24 hour | Magnesium | n/a | 3 days | Clinical Biochemistry | |
| 24 | Serum | Magnesium | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
14 | Whole Blood | Malaria Parasites | 4 mL | 24 hours, 7 working days if sent to Referral Laboratory for confirmation | Haematology |
|
10 | Whole Blood | Manganese | 5 mL | 14 days | Clinical Biochemistry |
| 24 | Serum | Mannose Binding Lectin | 2 mL | 14 working days | Immunology | |
|
14 | Whole Blood | Manual Blood Film including White Cell differential | 24 hours | Haematology | |
|
24 | Serum | Mast Cell Tryptase | 2 mL | 9 working days | Immunology |
| 14 | Whole Blood | MCH | 4 mL | 24 hours | Haematology | |
| 14 | Whole Blood | MCHC | 4 mL | 24 hours | Haematology | |
| 8 | Whole Blood | MCS (Blood Culture) | Adults: 8-10mL blood per blood culture bottle; Paeds: 1-3mL blood. Wherever possible, please ensure that each bottle of the blood culture set is inoculated with the correct volume of blood. Smaller volumes adversely affect the sensitivity of the assay. | 6 days | Microbiology | |
| 34 | CSF | MCS (Cerebrospinal fluid) | 3 mL | 4 hours Microscopy 4 days Culture & sensitivities |
Microbiology | |
| Corneal Scrapes | MCS (Corneal Scrapes) | 10 days | Microbiology | |||
| 7 | Swab | MCS (Ear / left / right) | n/a | 4 days | Microbiology | |
| 7 | Swab | MCS (Eye / left / right) | n/a | 4 days | Microbiology | |
|
11 | Faeces | MCS (Faeces) | 1/3 full/10ml minimum | 4 days | Microbiology |
| 34 | Fluid | MCS (Fluids) | 3 mL | 8 days | Microbiology | |
| 7 | Swab | MCS (Genital Swabs) | n/a | 4 days | Microbiology | |
| 7 | Mouth | MCS (Mouth Swab) | n/a | 4 days | Microbiology | |
| 7 | MCS (Nose swab) | n/a | 4 days | Microbiology | ||
| 41 | Penile / Urethral | MCS (Penile / Urethral swab) | n/a | 4 days | Microbiology | |
| 34 | Peritoneal fluid | MCS (Peritoneal Dialysis fluid) | n/a | 8 days | Microbiology | |
| 34 | Pus | MCS (Pus) | n/a | 10 days | Microbiology | |
| 7 | Swab | MCS (Skin swab) | n/a | 4 days | Microbiology | |
| 34 | Sputum | MCS (Sputum) | n/a | 5 days | Microbiology | |
| 7 | Swab | MCS (Throat swab) | n/a | 4 days | Microbiology | |
| 34 | Tip | MCS (Tip) | n/a | 4 days | Microbiology | |
| 34 | Tissue | MCS (Tissues) | n/a | 10 days | Microbiology | |
| 34 | Trachael aspirate | MCS (Tracheal aspirate) | n/a | 4 days | Microbiology | |
| 28 | Urine | MCS (Urine Catheter) | > 3 ml | 3 days | Microbiology | |
| 28 | Urine | MCS (Urine) | > 3 ml | 3 days | Microbiology | |
| 7 | Swab | MCS (Wound Swab) | n/a | 4 days | Microbiology | |
| 14 | Whole Blood | MCV | 4 mL | 24 hours | Haematology | |
| 24 | Clotted blood sample | Measles IgG | 0.17 | 4 days | Virology | |
| 24 | Clotted blood samples | Measles IgG and IgM | 0.19 | 4 days | Virology | |
| 43 | Swabs (nose and throat) | Measles PCR PCR (In house) |
0.5 | 3 days | Virology | |
| 35 | Urine - Random | Mercury | 1 mL | 14 days | Clinical Biochemistry | |
|
14 | Whole Blood | Mercury | 1 mL | 14 days | Clinical Biochemistry |
|
24 | Serum | Meropenem | <3 days | Antimicrobial Reference Laboratory | |
| 43 | Swabs (nose and throat) | MERS-CoV Molecular assay (NAAT) Biofire Film array RP2 |
0.5 | 4 hours from receipt for initial screening. | Virology | |
|
24 | Serum | Mesothelin | 2 ml | Please note this test is not currently available. For further information or enquires please contact the Immunology laboratory 0117 4148366 | Immunology |
|
4 | Urine - 24 hour | Metadrenalines | n/a | 7 days | Clinical Biochemistry |
|
14 | Whole Blood | Metadrenalines (Plasma) | 4 mL | 2 weeks | Clinical Biochemistry |
| 17 | Plasma | Methanol | 5 mL | 1 day | Clinical Biochemistry | |
| 34 | Fluids - e.g. CSF, vitreous | Microscopy and Culture | 200µL | Microscopy mean 1 day | Mycology Reference Laboratory | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Microscopy and Culture | 300µL | Microscopy mean 1 day | Mycology Reference Laboratory | |
| 34 | Tissue - e.g. lung biopsy, corneal scraping | Microscopy and Culture | Microscopy mean 1 day | Mycology Reference Laboratory | ||
| 34 | Fluids - e.g. CSF, vitreous | Microscopy and Culture | 200µL | Microscopy mean 1 day | Mycology Reference Laboratory | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Microscopy and Culture | 300µL | Microscopy mean 1 day | Mycology Reference Laboratory | |
| 34 | Tissue - e.g. lung biopsy, corneal scraping | Microscopy and Culture | Microscopy mean 1 day | Mycology Reference Laboratory | ||
| Microscopy for Crystals | Cytology | |||||
| 24 | Serum | Mitochondrial antibody | 2 mL | 4 working days | Immunology | |
| 35 | Urine - Random | MMA | 5 mL | 28 days | Clinical Biochemistry | |
| 24 | Serum | MMA | 2 mL | 20 days | Clinical Biochemistry | |
| 43 | Swabs (nose and throat) | Molecular assay (NAAT) Biofire Film array RP2 | 0.5 | 4 hours from receipt. | Virology | |
|
24 | Serum | Moxifloxacin | <3 days | Antimicrobial Reference Laboratory | |
| 14 | Bone Marrow | MRD Flow Cytometry | 0.5 mL | 1 working day | Immunology | |
| 35 | Urine - Random | Mucopolysaccharide screen | 5 mL | 14 days | Clinical Biochemistry | |
| 24 | Clotted blood sample | Mumps IgG | 0.17 | 4 days | Virology | |
| 23 | Skin | Mycology Skin Scrapings |
n/a | 15 days | Microbiology | |
| 23 | Hair | Mycology Hair | n/a | 15 days | Microbiology | |
| 23 | Nail clippings | Mycology Nail | n/a | 15 days | Microbiology | |
|
14 | Whole Blood | Mycophenolate | 4 mL | 14 days | Clinical Biochemistry |
| 45 | Aptima Swab or urine with a Copan or virocult swab | Mycoplasma Genitalium | 1 tube | 3 days | Virology | |
| 43 | Swabs (nose and throat) | Mycoplasma pneumoniae Molecular assay (NAAT) Biofire Film array RP2 |
0.5 | 4 hours from receipt. | Virology | |
| Myoglobin - Urine | ||||||
| 24 | Serum | Myositis line blot | 2ml | 2 weeks | Immunology | |
| 34 | Urine - Random | NAG: Creatinine ratio | 1 mL | 4 weeks | Clinical Biochemistry | |
| 38 | Aptima Urine | Neisseria gonorrhoeae NAAT |
1 tube | 3 days | Virology | |
| 1 | Aptima Swab | Neisseria gonorrhoeae NAAT |
1 tube | 3 days | Virology | |
| 44 | Whole Blood | Neonatal Blood Group | 1 mL | 24 hours | Blood Transfusion | |
| 44 | Whole Blood | Neonatal Crossmatch - Blood Transfusion | 1 mL | See Notes | Blood Transfusion | |
| 44 | Whole Blood | Neonatal DAT | 1 mL | 24 hours | Blood Transfusion | |
|
24 | Serum | Neuron Specific Enolase | 5 mL | 3 days | Clinical Biochemistry |
| 24 | Serum | Neuronal Antibody (Purkinje) | 2 mL | 14 working days | Immunology | |
|
14 | Plasma | Neurotensin | 5 mL | 28 days | Clinical Biochemistry |
|
32 | CSF | Neurotransmitters | see notes | 4 - 6 weeks | Clinical Biochemistry |
|
20 | Whole Blood | Neutrophil Function Tests | 7 mL | 2 working days | Immunology |
| 9 | Blood spot | Newborn Screen | 4x Spots | Clinical Biochemistry | ||
| 11 | Faecal sample | Norovirus PCR |
pea sized amount | 2 days | Microbiology | |
| 24 | Serum | NT-Pro-BNP | 5 mL | 1 day | Clinical Biochemistry | |
| 24 | Serum | Oestradiol | 5 mL | 1 day | Clinical Biochemistry | |
|
25 | Serum and CSF | Oligoclonal bands | 200ul CSF, 200ul Serum | 5 working days | Immunology |
| 34 | CSF | Orexin | 2mL | 42 days | Clinical Biochemistry | |
| 35 | Urine - Random | Organic acids | 5 mL | 14 days | Clinical Biochemistry | |
| 35 | Urine - Random | Orotic acid | 5 mL | 14 days | Clinical Biochemistry | |
| 35 | Urine - Random | Osmolality | 5 mL | Hospital patients 8 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | Osmolality | 5 mL | Hospital patients 8 hours; GP patients 24 hours | Clinical Biochemistry | |
| 11 | Faeces/ Urine | Ova Cysts & Parasites Faeces/ Urine - Concentrate | Minimum volume: 1/3 full/10ml minimum | 4 days | Microbiology | |
| 24 | Serum | Ovarian Antibody | 2 mL | 21 working days | Immunology | |
|
14 | Plasma | Oxalate | 5 mL | 14 days | Clinical Biochemistry |
|
4 | Urine - 24 hour | Oxalate | n/a | 7 days | Clinical Biochemistry |
| 24 | Serum | Pancreatic Islet Cell Antibody | 2 mL | 14 working days | Immunology | |
|
14 | Plasma | Pancreatic Polypeptide | 5 mL | 28 days | Clinical Biochemistry |
| 24 | Serum | Paracetamol | 5 mL | 4 hours | Clinical Biochemistry | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Paraflu 1 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Paraflu 1 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Paraflu 2 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Paraflu 2 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Paraflu 2 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Paraflu 3 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Paraflu 3 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Paraflu 3 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Paraflu 4 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Paraflu 4 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Paraflu 4 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Paraflu1 Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 24 | Serum | Paraneoplastic line blot | 2ml | 2 weeks | Immunology | |
| 14 | EDTA Blood sample | Parvovirus PCR (In house) |
0.45 | 3 days | Virology | |
| 34 | Amniotic fluid | Parvovirus PCR (In house) |
0.2 | 3 days | Virology | |
| 24 | Clotted blood samples | Parvovirus IgG and IgM | Parvovirus IgG 0.17mL, Parvovirus IgG and IgM 0.19mL | 4 days | Virology | |
|
24 | Serum | Phenobarbitone | 5 mL | 1 day | Clinical Biochemistry |
| 9 | Blood spot | Phenylalanine | 2x Spots | 5 days | Clinical Biochemistry | |
|
24 | Serum | Phenytoin | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry |
| 4 | Urine - 24 hour | Phosphate | n/a | 3 days | Clinical Biochemistry | |
| 24 | Serum | Phosphate | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 20 | Plasma | Phytanic acid | 2 mL | 21 days | Clinical Biochemistry | |
|
24 | Serum | PIIINP | 2 mL | 4-6 weeks | Clinical Biochemistry |
|
24 | Serum | Piperacillin | <3 days | Antimicrobial Reference Laboratory | |
|
13 | Plasma | PIVKA II | 10 days | Haematology | |
| 14 | Whole Blood | Plasma Viscosity | 4 mL | 3 days | Haematology | |
| 14 | Whole Blood | Platelet count (EDTA & Citrate) | 4 mL | 24 hours | Haematology | |
| 14 | See Notes | PNH Immunophenotyping | 3 mL | 4 working days | Immunology | |
|
14 | Whole Blood | Porphyrin Enzyme/DNA analysis | 4 mL | 28 days | Clinical Biochemistry |
|
14 | Whole Blood | Porphyrins | 5-10 mL | 15 days | Clinical Biochemistry |
|
11 | Faeces | Porphyrins | 5 g | 15 days | Clinical Biochemistry |
|
34 | Urine - Random | Porphyrins | 10 mL | 15 days | Clinical Biochemistry |
|
Serum | Posaconazole | < 2 days | Antimicrobial Reference Laboratory | ||
| 5 | Urine | Potassium | n/a | 1 day | Clinical Biochemistry | |
| 24 | Serum | Potassium | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | Prednisolone | 5 mL | 21 days | Clinical Biochemistry | |
| 24 | Serum | Progesterone | 5 mL | 1 day | Clinical Biochemistry | |
| 24 | Serum | Prolactin | 5 mL | 1 day | Clinical Biochemistry | |
| 35 | Urine - Random | Protein | 5 mL | 1 day | Clinical Biochemistry | |
| 34 | CSF | Protein | 2 mL | 4 hours | Clinical Biochemistry | |
| 34 | Dialysate | Protein | 5 mL | 8 hours | Clinical Biochemistry | |
| 24 | Serum | Protein | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Fluid | Protein | 5 mL | 3 days | Clinical Biochemistry | |
| 13 | Whole Blood | Protein C | 3 full tubes | 21 days | Haematology | |
| 13 | Whole Blood | Protein S | 3 full tubes | 21 days | Haematology | |
| 13 | Whole Blood | Prothrombin Gene Mutation | 3 full tubes | 1 month | Haematology | |
| 24 | Serum | PSA | 5 mL | 1 day | Clinical Biochemistry | |
| 14 | Plasma | PTH | 5 mL | 1 day | Clinical Biochemistry | |
| 32 | PTH-related peptide | Clinical Biochemistry | ||||
|
35 | Urine - Random | Purine / Pyrimidine Screen | 5 mL | 21 days | Clinical Biochemistry |
|
14 | Plasma | Pyruvate Kinase | 21 days | Haematology | |
|
32 | See Notes | Quantiferon | 7 working days | Immunology | |
| 24 | Serum | RAST | 2 mL | Immunology | ||
| 14 | Whole Blood | Red Blood Count | 4 mL | 24 hours | Haematology | |
| Red cell Transketolase | ||||||
| 14 | Plasma | Renin | 5 mL | 28 days | Clinical Biochemistry | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Respiratory Syncytial Virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Respiratory Syncytial Virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Respiratory syncytial virus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 14 | Whole Blood | Reticulocytes | 4 mL | 24 hours | Haematology | |
|
34 | Urine - Random | Retinol Binding Protein | 20 mL | 14 days | Clinical Biochemistry |
| 24 | Serum | Rheumatoid Factor | 2 mL | 3 working days | Immunology | |
| 34 | Bronchoalveolar lavage (BALs) and Sputums | Rhinovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 43 | Swabs (nose and throat) | Rhinovirus Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
| 34 | Nasopharayngeal aspirates (NPAs) | Rhinoviurs Molecular assay (NAAT) |
0.5 | 2 days | Virology | |
|
24 | Serum | Rifabutin | <3 days | Antimicrobial Reference Laboratory | |
|
24 | Serum | Rifampicin | <3 days | Antimicrobial Reference Laboratory | |
| 13 | Whole Blood | Ristocetin Co Factor. | 2.7 mL | 21 days | Haematology | |
| 14 | Whole blood | Rituximab | 3ml | 2 working days | Immunology | |
| 11 | Faecal sample | Rotavirus PCR |
pea sized amount | 2 days | Microbiology | |
| 24 | Clotted blood samples | Rubella IgG and IgM | Parvovirus IgG 0.17mL, Parvovirus IgG and IgM 0.19mL | 4 days | Virology | |
| 24 | Serum | Salicylate | 5 mL | 4 hours | Clinical Biochemistry | |
| 24 | Serum | Salivary Gland Antibodies | 2 mL | 21 working days | Immunology | |
| 11 | Faecal sample | Sapovirus PCR |
pea sized amount | 2 days | Microbiology | |
| 24 | Serum | Selenium | 5 mL | 7 days | Clinical Biochemistry | |
|
5 | Urine - 24 hour | Selenium | n/a | 14 days | Clinical Biochemistry |
| 24 | Serum | Serum Electrophoresis | 2 mL | 5 working days | Immunology | |
| 24 | Serum | SHBG | 5 mL | 7 days | Clinical Biochemistry | |
|
24 | Serum | Short Synacthen Test | 5 mL | 1 day | Clinical Biochemistry |
| 35 | Urine - Random | Sialic acid | 5 mL | 14 days | Clinical Biochemistry | |
| 14 | Whole Blood | Sickle Cell Screen | 4 mL | 24 hours (confirmatory testing); 1 hour (urgent and request phoned through to lab) | Haematology | |
| 14 | Whole Blood | Sirolimus | 4 mL | 3 days | Clinical Biochemistry | |
| 24 | Serum | Skeletal Muscle Antibody | 2 mL | 21 working days | Immunology | |
| 24 | Serum | Skin Antibody (Pemphigus/Pemphigoid) | 2 mL | 14 working days | Immunology | |
| 24 | Serum | Smooth Muscle Antibody | 2 mL | 4 working days | Immunology | |
| 35 | Urine - Random | Sodium | 5 mL | 1 day | Clinical Biochemistry | |
| 24 | Serum | Sodium | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
14 | Plasma | Somatostatin | 5 mL | 28 days | Clinical Biochemistry |
|
5 | Urine - 24 hour | Steroid Profile (urine) | n/a | 14 days | Clinical Biochemistry |
| 34 | Stone | Stones - Renal Calculi | n/a | 14 days | Clinical Biochemistry | |
| 24 | Clotted blood sample | Streptococcus serology (antistreptolysin O) ASO |
0.15 | 6 days | Virology | |
|
24 | Serum | Streptomycin | <3 days | Antimicrobial Reference Laboratory | |
|
24 | Serum | Sulphamethoxazole in Co-trimoxazole | <3 days | Antimicrobial Reference Laboratory | |
|
24 | Serum | Sulphonylurea | 5 mL | 28 days | Clinical Biochemistry |
| 24 | Clotted blood samples | Syphilis RPR |
0.5 | 4 days - Confirmations | Virology | |
| 24 | Clotted blood samples | Syphilis confirmation testing - IgG and IgM; Treponemal serology | 0.5 | 4 days - Confirmations | Virology | |
| 43 | Copan swab | Syphilis PCR | 1 tube | 10 days | Virology | |
| 24 | Clotted blood sample | Syphilis serology Total Antibody - Screening |
0.5 | 3 days - Screen | Virology | |
| 24 | Serum | Systemic Sclerosis line blot | 2ml | 2 weeks | Immunology | |
| 14 | Whole Blood | T Cell Subsets (see CD4 Counts) | 3 mL | 1 working day | Immunology | |
|
14 | Whole Blood | Tacrolimus | 4 mL | 3 days | Clinical Biochemistry |
| 39 | Whole Blood | TB (Mycobacterium Blood) | 3-5 mL | 70 days | Microbiology | |
| 6 | Urine | TB (Mycobacterium Urine) | 250 mL | 70 days | Microbiology | |
| 34 | Sputum/ Pus/ Tissue, NOT Swabs | TB (Mycobacterium) samples (other than Blood/ Urine) | n/a | 70 days | Microbiology | |
|
24 | Serum | Teicoplanin | <2 days | Antimicrobial Reference Laboratory | |
| 24 | Serum | Testis Antibody | 2 mL | 21 working days | Immunology | |
|
24 | Serum | Testosterone | 5 mL | 1 day | Clinical Biochemistry |
| 24 | Serum | Testosterone confirmation | 1 mL | 14 days | Clinical Biochemistry | |
| 24 | Serum | Tetanus antibodies | 2 mL | 28 working days | Immunology | |
| 24 | Serum | TFT confirmation | 1 mL | 3 weeks | Clinical Biochemistry | |
| 24 | Serum | Theophylline | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
14 | Whole Blood | Thiopurine Metabolites | 4 mL | 21 days | Clinical Biochemistry |
| 14 | Whole Blood | Thiopurine methyl transferase | 4 mL | 14 days | Clinical Biochemistry | |
| 0 | Rectal suspension kit | Threadworm | 4 days | Microbiology | ||
|
13 | Whole Blood | Thrombophilia Screen | 3 full tubes | 21 days | Haematology |
| 24 | Serum | Thyroglobulin | 5 mL | 7 days | Clinical Biochemistry | |
| 24 | Serum | Thyroid Function Tests | 5 mL | 1 day | Clinical Biochemistry | |
| 24 | Serum | Thyroid Peroxidase Antibody | 2 mL | 7 days | Clinical Biochemistry | |
| 24 | Serum | Tissue Transglutaminase Antibody | 2 mL | 7 working days | Immunology | |
|
24 | Serum | Tobramycin | <1 day | Antimicrobial Reference Laboratory | |
|
24 | Serum | Total Bile Acids | 5 mL | 1 day | Clinical Biochemistry |
| 24 | Serum | Total Protein | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Clotted blood samples | Toxoplasma Total antibody & IgM |
0.5 | 5 days | Virology | |
| 24 | Serum | Transferrin Glycoforms | 5 mL | 14 days | Clinical Biochemistry | |
|
16 | Whole Blood | Transfusion Reaction | 6ml | 24 hours | Blood Transfusion |
| 1 | Aptima Swab | Trichomonas vaginalis NAAT |
1 tube | 3 days | Virology | |
| 24 | Serum | Triglycerides | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
24 | Serum | Trimethoprim in Co-trimoxazole | <3 days | Antimicrobial Reference Laboratory | |
| 4 | Urine - 24 hour | Trimethylamine | n/a | 8 weeks | Clinical Biochemistry | |
| 24 | Serum | Troponin I | 5 mL | 4 hours | Clinical Biochemistry | |
| 9 | Blood spot | TSH | 2x Spots | 7 days | Clinical Biochemistry | |
| 24 | Serum | TSH Receptor Antibodies | 2ml | 8 working days | Immunology | |
| 24 | Serum | U/E (Urea and Electrolytes) | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 24 | Serum | Urate | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
|
3 | Urine - 24 hour | Urate | n/a | 1 day | Clinical Biochemistry |
| 24 | Serum | Urea | 5 mL | Hospital patients 4 hours; GP patients 24 hours | Clinical Biochemistry | |
| 5 | Urine | Urine Electrolytes | n/a | 1 day | Clinical Biochemistry | |
| 35 | Urine - Random | Urine Electrophoresis | 1 mL | 5 working days | Immunology | |
|
5 | Urine - 24 hour | Urine Free Cortisol | n/a | 2-3 weeks | Clinical Biochemistry |
| Urine reducing substances | ||||||
| 5 | Urine | Urine Urea | n/a | 1 day | Clinical Biochemistry | |
| 5 | Urine - 24 hour | Urine volume | n/a | 2 days | Clinical Biochemistry | |
|
24 | Serum | Valproate | 5 mL | 7 days | Clinical Biochemistry |
|
24 | Serum | Vancomycin | 5mL | Hospital patients 4 hours | Clinical Biochemistry |
| 34 | Lesion/vesicle fluid | Varicella zoster PCR (In house) |
0.5 | 3 days | Virology | |
| 43 | Vesicle Swab | Varicella zoster PCR (In house) |
0.5 | 4 days | Virology | |
| 14 | EDTA Blood sample | Varicella zoster PCR (In house) |
0.45 | 3 days | Virology | |
| 34 | CSF | Varicella Zoster PCR (In house) |
0.2 | 3 days | Virology | |
| 24 | Clotted blood samples | Varicella zoster IgG | 0.17 | 3 days | Virology | |
| 24 | Serum | VEGF | 2 mL | 21 days | Clinical Biochemistry | |
| 20 | Plasma | Very long chain fatty acids | 2 mL | 21 days | Clinical Biochemistry | |
|
14 | Plasma | VIP | 5 mL | 28 days | Clinical Biochemistry |
| Whole Blood | Viral Haemorrhagic Fever | 7 mL | 1 day | Virology | ||
| 0 | Various | Virology/ Serology (referred tests) | n/a | 10 days | Virology | |
| 24 | Serum | Vitamin A | 2 mL | 14 days | Clinical Biochemistry | |
|
14 | Whole Blood | Vitamin B1 | 4 mL | 2 weeks | Clinical Biochemistry |
| 24 | Serum | Vitamin B12 | 5 mL | 3 days | Clinical Biochemistry | |
|
14 | Whole blood | Vitamin B6 | 4 mL | 3 weeks | Clinical Biochemistry |
|
20 | Plasma | Vitamin C | 2 mL | 4 weeks | Clinical Biochemistry |
| 24 | Serum | Vitamin D | 5 mL | 7 days | Clinical Biochemistry | |
| 24 | Serum | Vitamin E | 2 mL | 14 days | Clinical Biochemistry | |
| 35 | Urine - Random | VMA | 5 mL | 7 days | Clinical Biochemistry | |
| 13 | Whole Blood | Von Willebrand's Disease | 2.7 mL | 3 weeks | Haematology | |
|
Serum | Voriconazole | < 2 days | Antimicrobial Reference Laboratory | ||
|
13 | Plasma | Warfarin levels | 10 days | Haematology | |
|
27 | Serum and Urine | Water Deprivation Test | see notes | 1 day | Clinical Biochemistry |
| 14 | Whole Blood | White Blood Count | 4 mL | 24 hours | Haematology | |
|
14 | Whole Blood | White Cell Enzymes | 5 mL | 3-4 weeks | Clinical Biochemistry |
|
34 | CSF | Xanthochromia | 1 mL | 4 hours | Clinical Biochemistry |
|
10 | Plasma | Zinc | 5 mL | 7 days | Clinical Biochemistry |
| Zinc Protoporphyrin |
Medical Same Day Emergency Care (SDEC)
Medical Same Day Emergency Care (SDEC)
Medical Same Day Emergency care (SDEC) is situated at Gate 36, Level 1, within the Emergency Zone, Brunel building.
The Same Day Emergency Care Unit provides:
- assessment
- investigation
- diagnosis
- management of patients with an acute illness within 1 day.
The Same Day Emergency Care team consists of consultants, nurses, pharmacists, junior doctors, advanced practitioners, and physician associates. Support is provided to the team by specialist nurses and doctors in other specialties.
Related links
Related links for clinicians
Contact the Medical SDEC team
Medical Same Day Emergency Care
Gate 36
Level 1
Brunel building
Southmead Hospital
BS10 5NB
Phone: 0117 414 7408